CYTOKINETICS INC
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNo. · Form · File No. · Filing Date · Exh.No. · FiledHerewith | ||||||
| 3.1 | Amended and Restated Certificate of Incorporation | S-3 | 333-174869 | June 13, 2011 | 3.1 | |
| 3.2 | Certificate of Amendment of Amended and Restated Certificate of Incorporation | 10-Q | 000-50633 | August 4, 2011 | 3.2 | |
| 3.3 | Certificate of Amendment of Amended and Restated Certificate of Incorporation | 8-K | 000-50633 | June 25, 2013 | 5.1 | |
| 3.4 | Certificate of Amendment of Amended and Restated Certificate of Incorporation | 8-K | 000-50633 | May 20, 2016 | 3.1 | |
| 3.5 | Certificate of Amendment of Amended and Restated Certificate of Incorporation | 10-Q | 000-50633 | August 3, 2023 | 3.5 | |
| 3.6 | Amended and Restated Bylaws | 8-K | 000-50633 | February 17, 2023 | 3.1 | |
| 4.1 | Specimen Common Stock Certificate | 10-Q | 000-50633 | May 9, 2007 | 4.1 | |
| 4.2 | Form of Warrant Issuable to Oxford Finance LLC pursuant to that certain Loan and Security Agreement, dated as of May 17, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank | 10-Q | 000-50633 | August 9, 2019 | 4.2 | |
| 4.3 | Base Indenture, dated November 13, 2019, between the Company and U.S. Bank National Association, as Trustee | 8-K | 000-50633 | November 13, 2019 | 4.1 | |
| 4.4 | First Supplemental Indenture, dated November 13, 2019, between the Company and U.S. Bank National Association, as Trustee (including the form of 4.00% Convertible Senior Notes due 2026) | 8-K | 000-50633 | November 13, 2019 | 4.2 | |
| 4.5 | Indenture, dated July 6, 2022, between the Company and U.S. Bank Trust Company, National Association, as Trustee (including the form of 3.50% Convertible Senior Notes due 2027) | 8-K | 000-50633 | July 6, 2022 | 4.1 | |
| 4.6 | Certificate of Designation | 8-K | 000-50633 | April 18, 2011 | 4.5 | |
| 4.7 | Certificate of Designation | 8-K | 000-50633 | June 30, 2012 | 4.1 | |
| 4.8 | Certificate of Change of Registered Agent | 10-K | 000-50633 | March 1, 2023 | 4.9 | |
| 10.1+ | Employment Offer Letter between Cytokinetics, Incorporated and Sung H. Lee | X | ||||
| 10.2+ | Cytokinetics, Incorporated Amended and Restated 2015 Employee Stock Purchase Plan | 8-K | 000-50633 | May 17, 2024 | 10.1 | |
| 10.3# | Third Amendment, dated May 22, 2024, to Development Funding Loan Agreement, dated January 7, 2022, by and among Royalty Pharma Development Funding, LLC and the Company | X | ||||
| 10.4# | Amendment No. 1, dated May 22, 2024, to Revenue Participation Right Purchase Agreement, dated January 7, 2022, by and between Royalty Pharma Investments 2019 ICAV and the Company | X | ||||
| 10.5# | 2024 Development Funding Loan Agreement, dated May 22, 2024, by and among Royalty Pharma Development Funding, LLC and the Company | X | ||||
| 10.6# | CK-586 Revenue Participation Right Purchase Agreement, dated May 22, 2024, by and between Royalty Pharma Investments 2019 ICAV and the Company | X |
| 10.7# | Common Stock Option and Purchase Agreement, dated May 22, 2024, by and between Royalty Pharma Investments 2019 ICAV and the Company | X |
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended | X |
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended | X |
| 32.1 | Certifications of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002(2) | X |
| 101.INS | Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Document | X |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | X |
Portions of this Exhibit have been omitted because they are immaterial and are of the type of information Cytokinetics treats as private or confidential.
- Management contract or compensatory plan or arrangement.
(1)
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.